suratadenoturev
AXP000034.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, hTERT promoter-driven E1A-IRES-E1B)
- Originator
- Oncolys BioPharma
- Sponsor
- Oncolys BioPharma
Names
| Name | Type | Source |
|---|---|---|
| suratadenoturev | preferred name, INN | curator, ncit |
| Telomelysin | brand | ncit |
| OBP-301 | code | ncit |
| Telomelycin | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (OBP-301)
- Replication
- conditionally replicating
- Modifications
- hTERT promoter drives E1A and E1B through an IRES
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C119617
- FDA UNII
- FV0JG1SX76
Approvals
No regulatory approval recorded.
Clinical trials (8)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06340711 | Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma | Recruiting | Phase 2 | 2024-04-25 | 2028-04 | 27 | Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma |
| NCT04391049 | Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery | Active not recruiting | Phase 1 | 2021-12-02 | 2024-10-06 | 16 | Advanced Esophageal Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage III Esophageal Adenocarcinoma AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage II Esophageal Adenocarcinoma AJCC v8; Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Esophageal Adenocarcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Squamous Cell Cancer; Squamous Cell Carcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma |
| NCT04685499 | Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease | Terminated | Phase 2 | 2021-05-03 | 2022-03-08 | 1 | Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease |
| NCT03921021 | Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma | Completed | Phase 2 | 2019-05-09 | 2023-06-20 | 17 | Esophagogastric Adenocarcinoma |
| NCT03172819 | Special Combination of OBP-301 and Pembrolizumab | Completed | Phase 1 | 2017-10-01 | 2021-04-06 | 22 | Advanced Solid Tumor |
| NCT03213054 | A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer | Unknown | Phase 1 | 2017-07-07 | 2019-03 | 12 | Esophageal Cancer |
| NCT03190824 | Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma | Unknown | Phase 2 | 2016-12-22 | 2021-06-24 | 4 | Melanoma Stage III; Melanoma Stage Iv |
| NCT02293850 | Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma | Unknown | Phase 1 | 2014-10 | 2019-04 | 18 | Carcinoma, Hepatocellular |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37060176 | Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial. | Molecular therapy : the journal of the American Society of Gene Therapy | 2023 | cited by trial NCT02293850 |
| PMID 34153720 | Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments. | European journal of cancer (Oxford, England : 1990) | 2021 | name in title: Telomelysin |
| PMID 19935775 | A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. | Molecular therapy : the journal of the American Society of Gene Therapy | 2010 | name in title: Telomelysin |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41315733 | p53-armed oncolytic adenovirus induces apoptosis in pancreatic cancer-associated stellate cells via macropinocytosis. | Cancer gene therapy | 2026 | name in abstract: OBP-301 |
| PMID 41469103 | P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors. | Anticancer research | 2026 | name in abstract: OBP-301 |
| PMID 41721933 | Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702). | International journal of clinical oncology | 2026 | name in abstract: suratadenoturev |
| PMID 41895769 | P53-armed Oncolytic Adenovirus Enhances the Efficacy of PD-1 Blockade in Neuroblastoma by Inducing Immunogenic Cell Death. | Anticancer research | 2026 | name in abstract: OBP-301 |
| PMID 42005830 | Mitochondrial inhibition enhances the sensitivity of pancreatic ductal adenocarcinoma cells to oncolytic adenovirus. | Molecular therapy. Oncology | 2026 | name in abstract: OBP-301 |
| PMID 42269787 | NRG-GI007: Phase 1 Study of OBP-301, An Oncolytic Virus, and Definitive Chemoradiation in Locally Advanced Esophageal Cancer. | International journal of radiation oncology, biology, physics | 2026 | name in title: OBP-301 |
| PMID 42795690 | Virotherapy for Spinal and Spinal Cord Tumors: Current Evidence and Future Perspectives. | Microorganisms | 2026 | name in abstract: OBP-301 |
| PMID 41188286 | Serum extracellular vesicles containing adenoviral E1A-DNA as a predictive biomarker for liquid biopsy in oncolytic adenovirus therapy. | Scientific reports | 2025 | name in abstract: OBP-301 |
| PMID 38377118 | Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus. | PloS one | 2024 | name in abstract: OBP-301 |
| PMID 38688833 | p53-Armed Oncolytic Virotherapy Improves Radiosensitivity in Soft-Tissue Sarcoma by Suppressing BCL-xL Expression. | Acta medica Okayama | 2024 | name in abstract: OBP-301 |
| PMID 39108499 | p53-armed oncolytic virotherapy induces abscopal effect in osteosarcoma by promoting immunogenic cell death. | Molecular therapy. Oncology | 2024 | name in abstract: OBP-301 |
| PMID 39499326 | Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity. | Cancer immunology, immunotherapy : CII | 2024 | name in abstract: OBP-301 |
| PMID 36669725 | Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma. | Cancer letters | 2023 | name in abstract: Telomelysin |
| PMID 37972012 | p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells. | PloS one | 2023 | name in abstract: OBP-301 |
| PMID 35503449 | Overexpression of Adenovirus E1A Reverses Transforming Growth Factor-β-induced Epithelial-mesenchymal Transition in Human Esophageal Cancer Cells. | Acta medica Okayama | 2022 | name in abstract: OBP-301 |
| PMID 35681700 | Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. | Cancers | 2022 | name in abstract: Telomelysin |
| PMID 36281608 | [Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2022 | name in abstract: OBP-301 |
| PMID 36381653 | An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma. | Molecular therapy oncolytics | 2022 | name in abstract: suratadenoturev |
| PMID 33477279 | Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment. | International journal of molecular sciences | 2021 | name in abstract: OBP-301 |
| PMID 33886686 | Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression. | PloS one | 2021 | name in abstract: OBP-301 |
| PMID 34023506 | Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles. | Molecular therapy : the journal of the American Society of Gene Therapy | 2021 | name in abstract: Telomelysin |
| PMID 34277838 | Current status of intralesional agents in treatment of malignant melanoma. | Annals of translational medicine | 2021 | name in abstract: Telomelysin |
| PMID 31991110 | Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. | Molecular therapy : the journal of the American Society of Gene Therapy | 2020 | name in abstract: Telomelysin |
| PMID 32085583 | Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy. | Cancers | 2020 | name in abstract: Telomelysin |
| PMID 32322667 | Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. | Molecular therapy oncolytics | 2020 | name in abstract: OBP-301 |
| PMID 32637577 | Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression. | Molecular therapy oncolytics | 2020 | name in abstract: OBP-301 |
| PMID 30462296 | Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. | Japanese journal of clinical oncology | 2019 | name in abstract: Telomelysin |
| PMID 31346579 | Multidisciplinary oncolytic virotherapy for gastrointestinal cancer. | Annals of gastroenterological surgery | 2019 | name in abstract: Telomelysin |
| PMID 30270333 | A Flow Cytometry-Based Method to Determine the Titer of Adenoviruses Expressing an Extraneous Gene. | Biological & pharmaceutical bulletin | 2018 | name in abstract: OBP-301 |
| PMID 27171483 | Therapeutic Cell-Cycle-Decoy Efficacy of a Telomerase-Dependent Adenovirus in an Orthotopic Model of Chemotherapy-Resistant Human Stomach Carcinomatosis Peritonitis Visualized With FUCCI Imaging. | Journal of cellular biochemistry | 2017 | name in abstract: OBP-301 |
| PMID 28685948 | Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction. | Cancer science | 2017 | name in abstract: OBP-301 |
| PMID 27356624 | Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas. | Scientific reports | 2016 | name in abstract: Telomelysin |
| PMID 27673332 | Efficacy of a Cell-Cycle Decoying Killer Adenovirus on 3-D Gelfoam®-Histoculture and Tumor-Sphere Models of Chemo-Resistant Stomach Carcinomatosis Visualized by FUCCI Imaging. | PloS one | 2016 | name in abstract: OBP-301 |
| PMID 26033451 | Targeting tumors with a killer-reporter adenovirus for curative fluorescence-guided surgery of soft-tissue sarcoma. | Oncotarget | 2015 | name in abstract: OBP-301 |
| PMID 23728900 | Telomerase-specific oncolytic adenovirus: antitumor effects on radiation-resistant head and neck squamous cell carcinoma cells. | Head & neck | 2014 | name in abstract: OBP-301 |
| PMID 22886913 | Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. | International journal of cancer | 2013 | name in abstract: Telomelysin |
| PMID 23315976 | Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. | Molecular cancer therapeutics | 2013 | name in abstract: OBP-301 |
| PMID 23718223 | Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells. | Cancer science | 2013 | name in title: Telomelysin |
| PMID 23863576 | [Current state of oncolytic virotherapy in Japan]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2013 | name in abstract: OBP-301 |
| PMID 24065118 | Antitumor effects of telomerase-specific replication-selective oncolytic viruses for adenoid cystic carcinoma cell lines. | Oncology reports | 2013 | name in abstract: Telomelysin |
| PMID 24081978 | A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S/G2/M phases. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2013 | name in abstract: OBP-301 |
| PMID 24356717 | Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. | Acta medica Okayama | 2013 | name in abstract: OBP-301 |
| PMID 21740362 | Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer. | Current pharmaceutical biotechnology | 2012 | name in abstract: Telomelysin |
| PMID 22244827 | A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. | European journal of cancer (Oxford, England : 1990) | 2012 | name in abstract: OBP-301 |
| PMID 22525466 | Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization. | Acta medica Okayama | 2012 | name in abstract: Telomelysin |
| PMID 22720091 | The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment. | PloS one | 2012 | name in abstract: Telomelysin |
| PMID 22956040 | Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells. | Cancer gene therapy | 2012 | name in abstract: Telomelysin |
| PMID 21193997 | Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus. | Journal of cancer research and clinical oncology | 2011 | name in abstract: Telomelysin |
| PMID 21325287 | Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2011 | name in abstract: OBP-301 |
| PMID 21362583 | Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines. | Auris, nasus, larynx | 2011 | name in title: Telomelysin |
| PMID 21504319 | Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer. | Expert review of anticancer therapy | 2011 | name in abstract: OBP-301 |
| PMID 21709712 | A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer. | Acta medica Okayama | 2011 | name in abstract: Telomelysin |
| PMID 19662088 | Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. | Cancer gene therapy | 2010 | name in abstract: Telomelysin |
| PMID 19935710 | A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. | Oncogene | 2010 | name in abstract: OBP-301 |
| PMID 20043095 | Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. | Oncology reports | 2010 | name in title: Telomelysin |
| PMID 20168351 | Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma. | Cancer gene therapy | 2010 | name in title: OBP-301 |
| PMID 20485131 | In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. | Annals of surgery | 2010 | name in abstract: Telomelysin |
| PMID 20501801 | Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. | Molecular cancer therapeutics | 2010 | name in abstract: Telomelysin |
| PMID 21045143 | Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. | Cancer research | 2010 | name in abstract: Telomelysin |
| PMID 18754077 | Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin). | Investigational new drugs | 2009 | name in title: Telomelysin |
| PMID 19139126 | Telomerase-specific virotherapy in an animal model of human head and neck cancer. | Molecular cancer therapeutics | 2009 | name in abstract: Telomelysin |
| PMID 19155526 | A novel antiangiogenic effect for telomerase-specific virotherapy through host immune system. | Journal of immunology (Baltimore, Md. : 1950) | 2009 | name in abstract: Telomelysin |
| PMID 19216621 | Telomerase-specific virotherapy for human squamous cell carcinoma. | Expert opinion on biological therapy | 2009 | name in abstract: Telomelysin |
| PMID 19318473 | Telomerase-specific virotheranostics for human head and neck cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2009 | name in abstract: OBP-301 |
| PMID 19372571 | Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. | Molecular cancer therapeutics | 2009 | name in abstract: Telomelysin |
| PMID 19461167 | [Oncolytic virotherapy for human solid tumors]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2009 | name in abstract: Telomelysin |
| PMID 19787218 | Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer. | Oncology reports | 2009 | name in title: Telomelysin |
| PMID 19798455 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2009 | name in abstract: OBP-301 |
| PMID 19887549 | Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. | Molecular cancer therapeutics | 2009 | name in abstract: Telomelysin |
| PMID 17981675 | Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents. | Frontiers in bioscience : a journal and virtual library | 2008 | name in abstract: Telomelysin |
| PMID 17982491 | Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. | Oncogene | 2008 | name in abstract: Telomelysin |
| PMID 18274558 | Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model. | Cancer gene therapy | 2008 | name in title: OBP-301 |
| PMID 18338751 | Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy. | International journal of cancer | 2008 | name in abstract: Telomelysin |
| PMID 18580968 | Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. | Gene therapy | 2008 | name in abstract: OBP-301 |
| PMID 18754863 | Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. | Cancer science | 2008 | name in abstract: Telomelysin |
| PMID 19020715 | Anti-tumor effects of telomelysin for head and neck squamous cell carcinoma. | Oncology reports | 2008 | name in title: Telomelysin |
| PMID 19122384 | Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. | Uirusu | 2008 | name in abstract: Telomelysin |
| PMID 17346111 | Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. | Current cancer drug targets | 2007 | name in abstract: Telomelysin |
| PMID 17926546 | [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer]. | Nihon rinsho. Japanese journal of clinical medicine | 2007 | name in abstract: Telomelysin |
| PMID 16356494 | Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. | Experimental cell research | 2006 | name in title: OBP-301 |
| PMID 16477640 | Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. | International journal of cancer | 2006 | name in abstract: Telomelysin |
| PMID 15735729 | Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). | Oncogene | 2005 | name in title: Telomelysin |
| PMID 15342413 | Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. | Cancer research | 2004 | name in abstract: Telomelysin |
Notes
Telomelysin/OBP-301. Telomerase (hTERT) promoter drives E1A and E1B via an IRES. Partnered with Chugai (Japan) and with Merck/Roche in combination studies at various times; partnership history not re-verified.
How to cite
suratadenoturev (AXP000034.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000034.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.